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CHRONIC graft-versus-host-disease (GVHD) is a de-bilitating and often fatal complication seen in 30% to 
60% of patients undergoing allogeneic bone marrow trans-
plantation (BMT).' Its prognosis is poorer with advancing 
patient age, when it is extensive. if it appears progressively 
after acute GVHO, if total bilirubin is more than 1.2 
mg/dL, or if the platelet count is less than lOO.OOO/mL. 
Conventional treatment includes combination immunosup-
pression most often with cyclosporine (CyA) and pred-
nisone. Azathioprine. methotrexate. antilymphocyte glob-
ulin. and other therapies may also be used. l~ 
FK 506 is a potent new immunosuppressive agent effec-
tive in rescue of solid organ transplant patients who failed 
conventional treatment for immunologically mediated 
damage. 7 
We attempted rescue of patients with severe chronic 
GVHO after BMT who had failed conventional treatment. 
INCLUSION CRITERIA 
Patients were accepted into the study if they had extensive 
chronic G VHD after failure of at least 2 months of first-line 
therapy. Alternatively, patients were entered if they dem-
onstrated unchanged symptomatology after 9 months of 
treatment, or had severe adverse reactions from drugs 
used in first-line treatment. 
EXCLUSIONS 
Three patients with severe chronic G VHO were not ac-
cepted for FK 506 treatment: I had coexistent necrotizing 
pancreatitis and 2 had aspergillus pneumonia. All 3 pa-
tients died from these complications within 2 weeks of 
referral. Three BMT patients received FK 506 for indica-
tions other than chronic GVHO (acute GVHD. n = I; 
veno-occlusive disease. n = 2) and are not included here. 
The first patient died of disseminated aspergillosis 3 days 
after FK 506 treatment was initiated. The latter 2 patients 
died of pulmonary complications after liver transplanta-
tion. 
TREATMENT PROTOCOL 
Initial FK 506 dose was 0.15 mgtkg BID orally or 0.15 
mg/kg per day IV. The dose was adjusted upward until a 
clinical response was seen, or at least to maintain a. blood 
level between 1 and 2 ng/mL. The dose was lowered if a 
clinically significant side effect occurred; most commonly 
the dose was lowered when there was evidence of progres-
sive nephrotoxicity. 
Corticosteroids were tapered to the lowest possible dose 
necessary to maintain clinical respo~K 
CyA and all other immunosuppressive agents. except 
steroids. were discontinued 24 to 48 hours prior to admin-
istration of FK 506. 
All patients received trimethoprim-sulfamethoxazole 
prophylaxis (one double-strength tablet PO BID twice 
weekly for adults or an equivalent dose for children). 
RESULTS 
Seventeen patients entered the study; their clinical profile 
is shown in Table 1. The preparative regimen, GVHD 
prophylaxis. and treatment received for chronic GVHO 
prior to entry into the study varied and are shown in Table 
2. 
All patients received CyA for GVHD prophylaxis and 
treatment of chronic GVHD most often in combination 
with prednisone and other immunosuppressive agents. 
The time elapsed between BMT and FK 506 treatment 
varied from 5 to 55 months (mean 21.4 months). Chronic 
GVHD developed de novo in one patient, was of the 
quiescent type in seven patients and of the progressive 
type in nine patients. Organs affected included liver, lungs, 
Table 1. Cllnlclll Profile (N = 17, All Patients) 
Age 
Children 4-12 years (mean .. 8.7) .. 5 patients 
Adults 16-47 years (mean .. 34.5) .. 12 patients 
Sex 
MaleIFemale: 1215 
Diagl10SlS 
Chronic myeloiclleukemia: 7 
Acute lymphoid leukemia: 4 
Acute myeloid leukemia: 2 
Aplastic anemia: 2 
Burkitt's lymphoma: 1 
San Fillippo syndrome: 1 
HLA matching 
Identical: 13" 
Nonidentical: 4 
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Table 2. Treatment Received Before FK 506 Rescue 
Preparative regimen: 
Variable: Cyclophosphamide. busulfan. TBI 
GVHD prophylaxis: 
CyA + prednisone: 8 
CyA + methotrexate: 3 
CyA + prednisone + azathiopnne: 4 
CyA + prednisone + methotrexate: 1 
CyA + methotrexate followed by CyA + prednisone + azathio-
prine: 1 
Chronic GVHD treatment: 
All patients receIVed CyA + prednisone 
Other agents used: azathioprine (7), ATG (2), xomazyme (2), 
PUVA (1) 
gastrointestinal tract. skin. musculoskeletal. and oral mu-
cosa. It involved two organs in four patients, three organs 
in five patients. four organs in four patients. five organs in 
three patients. and six organs in one patient. Nine patients 
had total serum bilirubin greater than 1.2 mg/dL. 10 
exhibited lichenoid skin histology, seven patients had lung 
involvement. 'and one patient had a platelet count of less 
than lOO.OOO/mL. 
Patient Survival 
Currently. 11 of the patients are alive and 6 are dead with 
a follow-up period of 3 to 16 months (mean 8.4 months). 
Two patients required liver transplantation after starting 
FK 506 treatment. One of them is alive and well 3 months 
following the procedure. and the second died of respira-
tory distress syndrome and multiorgan failure 8 weeks 
after transplantation. The results are summarized in Tables 
3 and 4. 
Response According to Systems Involved 
The organ systems involved demonstrated different re-
sponse to treatment independent of the patient's survival. 
Table 3. 
Results (all patients): 11 alive', 6 dead' 
Survival according to age 
Children: 4 alive, 1 dead 
Adults: 7 alive. 5 dead 
Survival according to system involved (all patients): 
Skin: 7 alive. 6 dead 
GI: 6 alive. 4 dead 
Lungs: 3 alive, 4 dead 
Musculoskeletal: 3 alive, 2 dead 
Survival according to type of onset (all patients): 
De novo: 1 alive. 0 dead 
QuiesCent: 4 alive. 3 dead 
Progr8SSIV8: 6 alive, 3 dead 
'IncIuding 1 cnild whO is aMve after IiIIer tra/1IIIIIIII1I 
'Including 1 adUlt whO died afIIIr IMIr 1r8IISI*InIatiO. Follow-up: 3-16 monlhl 
E~ 8.4 montns). 
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Table 4. Cllnai R...,onM to T....-....m (Survivors N. 11) 
Unambiguous Improvement: 6 patients 
Ambiguous Improvement 01' unchanged: 2 patients 
Stopped FK 506: 2 patients 
Alive after liver transplantation: 1 patient 
The skin and GI system showed unambiguous improve-
ment. Follow-up GI biopsies were performed in two chil-
dren, and both demonstrated disappearance of GVHD 
which was present in both al rescue. 
Musculoskeletal involvement showed no response to 
treatment. Lung involvement showed no change in four 
and deterioration in three patients. confirmed by pulmo-
nary function tests. 
Of the survivors, two patients who did not improve on 
FK 506 were converted to their original Cy A regimen. One 
patient is well after liver transplantation on FK 506 treat-
ment. Of the remaining eight patients. six showed unam-
biguous improvement. while two showed minor improve-
ment or remained unchanged and are still on FK 506. 
Uver InVOlvement 
The mean values of the liver enzymes at entry and at 
follow-up in patients who are alive with their native liver (n 
= 8) are shown in Fig 1. Fig 2 shows the changes of the 
mean total serum bilirubin of these patients. All of the 
patients had improvement. Four children had liver biop-
sies at 3 months and 6 months after FK 506 treatment was 
instituted. Despite clinical and biochemical improvements. 
there was no appreciable histological change as compared 
to pretreatment biopsies. 
Steroid Requirements 
Fig 3 shows the mean prednisone (prednisolone) dosage of 
these patients during follow-up. One of the children. as 
well as the child who received the liver transplant. are 
currently receiving no steroids. 
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Fig 2. Total bilirubin Esurvivo~ative liver with liver affect) (N = 
8). 
Complications 
An elevated serum creatinine level was common after 
conversion to FK 506 and decreased over time. Two 
patients currently have a serum creatinine of >2 mg/dL 
(2.4 mg/dL at 3 months after rescue. 2.2 mg/dL at 6 months 
after rescue). Two additional patients required dialysis in 
the treatment of multiorgan failure premonem. 
Eight patients are receiving treatment for hypenension. 
four of them were receiving such treatment before treat-
ment with FK 506. No patients developed diabetes melli-
tus or seizures. To the contrary, one patient who had 
repeated seizures on IV Cy A did not have any seizure 
activity on FK 506. 
Infections while under treatment with FK 506 are shown 
in Table 4. Of those. three were fatal. 
There was no loss of bone marrow graft or development 
of malignancies (recurrent or de novo) under FK 506 
therapy. 
DISCUSSION 
FK 506 rescue in chronic G VRO after BMT was attempted 
because of the potency of FK 506 and its known ability to 
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Fig 3. Dose of prednisone (SUMVOrS). 
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T ... 6. Inf1IctIona In FK 501 AHcue for Chronic GVHD 
BacIeriaI 
3 Broviac catheter sepsiS 
1 Streptococc:al pneumonia 
Viral 
1 Viral pneumonia" 
Fungal 
2 Asl*gillosis" 
1 Candida UTI 
·FaIIIIlnIectIon. 
rescue solid organ allografts. particularly livers. undergo-
ing chronic rejection even after failure of conventional 
therapy.7 Of the 17 patients reported here. 6 had a bene-
ficial response to FK 506 treatment. achieved with relative 
freedom from steroids. 
Nephrotoxicity was the most common side effect of FK 
506 treatment. It was consistently more severe soon after 
rescue and then tended to decrease with time and dose 
reduction. A similar effect has been seen in rescue of solid 
organ recipients and is thought to be. at least in part. an 
overlapping effect from FK 506 and Cy A. 7 
The increase in the number of patients receiving treat-
ment for hypenension is different than the experience with 
FK 506 for solid organ transplantation. 8 
An inherent difficulty of this study is the quantitative 
evaluation of the results. because of the variety of clinical 
presentations in the spectrum of chronic GVRO. 
The correction of abnormal liver function studies. pro-
vided an objective monitor of the response to treatment. 
The lack of histopathologic improvement in the available 
liver biopsies could be due to the subtlety of both pathol-
ogy and effect of FK treatment. Indeed. pathologic 
changes may require longer periods of time to resolve. 
Patients with pulmonary and musculoskeletal involve-
ment have. as yet. failed to improve with FK 506 treat-
ment. 
This pilot series suggests that FK 506 can be of help 
when conventional treatment has failed in the treatment of 
chronic GVRO foUowing BMT. It is possible that the 
apparent advantage is also evident if FK 506 is used earlier 
in the course of GVRO. 
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